Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients
- 1 December 2002
- journal article
- conference paper
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 8 (12) , 773-780
- https://doi.org/10.1046/j.1469-0691.2002.00510.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantationThe Lancet, 2000
- Randomized Trial of Weekly Sulfadoxine/Pyrimethamine vs. Daily Low‐Dose Trimethoprim‐Sulfamethoxazole for the Prophylaxis ofPneumocystis cariniiPneumonia After Liver TransplantationClinical Infectious Diseases, 1999
- CLINICAL SIGNIFICANCE OF VIRAL LOAD IN THE DIAGNOSIS OF CYTOMEGALOVIRUS DISEASE AFTER LIVER TRANSPLANTATIONTransplantation, 1998
- Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipientsThe Lancet, 1997
- Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantationJournal of Medical Virology, 1997
- Infections in solid-organ transplant recipientsClinical Microbiology Reviews, 1997
- Cytomegalovirus Infection Following Liver Transplantation: Review of the LiteratureClinical Infectious Diseases, 1996
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Cytomegalovirus Infection Persists in the Liver Graft in the Vanishing Bile Duct SyndromeHepatology, 1992
- A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart TransplantationNew England Journal of Medicine, 1992